Study of Combination Therapy for High Risk Prostate Cancer

Clinical Trial Title

Niraparib with standard combination radiation therapy and androgen deprivation therapy in treating patients with high risk prostate cancer.

Contact Information

Rush Cancer Center Clinical Trials Office

Clinical Trial Protocol Description:

This phase II trial studies the side effects and best dose of niraparib, and to see how well it works in combination with standard of care radiation therapy and hormonal therapy (androgen deprivation therapy) in treating patients with prostate cancer that has a high chance of coming back (high risk). Niraparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Adding niraparib to the usual treatments of radiation therapy and hormonal therapy may lower the chance of prostate cancer growing or returning.

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria:

  • Have histologically confirmed adenocarcinoma of the prostate at high risk for recurrence.
  • Have no distant metastases on bone scan or lymph node assessment.
  • Have no prior radical prostatectomy, cryosurgery for prostate cancer, or bilateral orchiectomy for any reason.
  • Have no prior systemic therapy for prostate cancer (prior therapy for a different cancer is allowable).

This is a partial list of inclusion and exclusion criteria.

Study Details

Clinical Trial Investigator

Dian Wang, MD, PhD

Contact Information

Rush Cancer Center Clinical Trials Office

Location

Rush University Medical Center

1620 W Harrison St
Chicago, IL 60612

Get Directions

Clinical Trial FAQs

Find out if a clinical trial makes sense for you.

Learn more
Learn more